Inactivated poliovirus vaccine and the final stages of poliovirus eradication.
The use of the inactivated poliovirus vaccine (IPV) will increase before and probably also after the global eradication of the wild type poliovirus. Before eradication, the switch from the use of oral poliovirus vaccine (OPV) to IPV has been due to the better safety record of IPV. Introduction of IPV in the regular immunisation schedules is made easier by the development of several combination vaccines, including IPV. Maternal antibodies and young age, often considered problematic for early initiation of IPV schedules, did not compromise optimal maintenance of seropositivity during infancy or long-term persisting antibody levels in our studies. OPV-derived, potentially pathogenic and transmissible poliovirus strains, excreted by some individuals for years, may present a problem for a blunt stopping of all polio immunisations after eradication. Our recent results suggest that locally excreted IgA might have a role in the elimination of poliovirus infection in the intestinal tissues.
The Enterovirus Laboratory, National Public Health Institute (KTL), Mannerheimintie 166, 00300, Helsinki, Finland. tapani.hovi@ktl.fi
T
T
Hovi
D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral; D005260:Female; D006801:Humans; D007112:Immunity, Maternally-Acquired; D018928:Immunity, Mucosal; D007223:Infant; D007700:Kinetics; D008459:Measles virus / Q000276:immunology / Q000302:isolation & purification; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D011247:Pregnancy; D012449:Safety
D000914:Antibodies, Viral; D000956:Antigens, Viral; D011054:Poliovirus Vaccine, Inactivated